A Single-Dose, Single Period, Phase II Pharmacokinetic Study To Examine Testagen TDS-Testosterone For Its Potential To Be Inadvertently Transferred By Skin Contact After Dosing In Healthy Adult Subjects
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Pharmacokinetics
- Acronyms TRANSFERENCE
- Sponsors Transdermal Delivery Solutions Corp
- 17 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Mar 2019.
- 17 Oct 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2018.
- 18 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2017.